Glycocalyx measurements in people with premature cardiovascular disease.

Registration Number: NL-OMON25534

Lead Sponsor: niversity of Maastricht, research institute CARIM

Brief Summary: /A

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 40

Inclusion Criteria

Cases: Male and female.

Subjects should have premature cardiovascular disease, which will be defined as cardiac, cerebral or peripheral vascular disease before the age of 40 years. Since a diminished glycocalyx volume is viewed as one of the first vascular alterations before overt atherosclerosis develops, we believe it is of no concern when the cardiovascular event had occurred. Furthermore, all of these subjects must have a positive family history for cardiovascular disease. This will be defined as at least one first degree or two or more second degree family members with cardiovascular disease before the age of 55 for men and before the age of 60 for women.

Exclusion Criteria

Cases:

Patients will be excluded if they have a positive history for hypertension, diabetes mellitus or other disease and in case of pregnancy or lactating women, if subjects are below the age of 18 years, or if subjects are unable to give informed consent.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The volume of the intravascular glycocalyx, before and after NTG administration, in subjects with premature atherosclerosis before the age of 40 years as compared to healthy control subjects.

Secondary Outcome Measures